X
ABUS icon

Xponance’s Arbutus Biopharma ABUS Stock Holding History

Xponance’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.1K Buy
15,432
+1,742
+13% +$7.65K ﹤0.01% 1747
2026
Q1 		$61.6K Buy
13,690
+1,814
+15% +$7.93K ﹤0.01% 1623
2025
Q4 		$57.1K Buy
11,876
+80
+0.7% +$360 ﹤0.01% 1512
2025
Q3 		$53.6K Buy
11,796
+174
+1% +$639 ﹤0.01% 1484
2025
Q2 		$35.9K Buy
11,622
+745
+7% +$2.47K ﹤0.01% 1474
2025
Q1 		$38K Buy
10,877
+391
+4% +$1.3K ﹤0.01% 1404
2024
Q4 		$34.3K Buy
+10,486
New +$38.6K ﹤0.01% 1414

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Xponance's ABUS Position: Q2 2026 in Review

Xponance increased its Arbutus Biopharma (ABUS) stake by 13% in Q2 2026, buying an estimated $7.65K and bringing the position to 15,432 shares worth $74.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1747.

Xponance first reported a position in ABUS in Q4 2024 and has held it in 7 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Xponance held 15,432 shares of Arbutus Biopharma worth $74.1K as of Q2 2026.
  • Xponance bought 1,742 Arbutus Biopharma shares in Q2 2026, an estimated $7.65K.
  • Arbutus Biopharma made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1747 holding.
  • Xponance first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 7 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.